Bone metastases, which are commonly seen in patients with advanced cancers, are a major cause of skeletal events, disability, and death. Radium-223 dichloride (radium-223; Xofigo, formerly Alpharadin), a first-in-class, alpha-emitting radiopharmaceutical that selectively targets bone metastases with high-energy short-range alpha-particles, has been approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases. Approval is based on results of the randomized phase III trial Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA), in which radium-223 prolonged overall survival and time to first symptomatic skeletal event versus placebo among patients with CRPC with symptomatic bone metastases and was generally well tolerated, with low myelosuppression rates and manageable gastrointestinal adverse events. Long-term follow-up of the ALSYMPCA safety population showed that the incidence of myelosuppression remained low among patients treated with radium-223, with no additional safety issues of acute myelogenous leukemia, myelodysplastic syndrome, aplastic anemia, or primary bone cancer within approximately 1.5 years after treatment. The radium-223 overall survival benefit and low toxicity make it an effective, well-tolerated, and novel treatment option for CRPC and symptomatic bone metastases and opens the possibility of exploring radium-223 in the treatment of bone metastases from other cancers. A phase I clinical trial of patients with breast and prostate cancer with skeletal metastases demonstrated that radium-223 was safe and well tolerated at all therapeutically relevant dosages. Moreover, a phase IIa trial of patients with advanced breast cancer and progressive bone-dominant disease demonstrated that radium-223 targeted areas of increased bone metabolism and showed biologic activity. I n advanced cancers, metastases to the bone are a major cause of morbidity and skeletal complications, such as bone pain, pathologic fracture, spinal cord or nerve root compression, and hypercalcemia. 1-3 Radium-223, a fırst-inclass alpha-emitting radiopharmaceutical with a potent and highly targeted cytotoxic effect on bone metastases, has been approved for the treatment of patients with castrationresistant prostate cancer (CRPC) and symptomatic bone metastases with no known visceral metastatic disease in fırst-line and postdocetaxel settings. 4 Here, we review the mechanism of action of radium-223; its use in the treatment of prostate and breast cancer with skeletal metastases, including results from the ALSYMPCA phase III clinical trials and long-term follow-up; and an overview of current and planned studies using this agent.
I n advanced cancers, metastases to the bone are a major cause of morbidity and skeletal complications, such as bone pain, pathologic fracture, spinal cord or nerve root compression, and hypercalcemia. [1] [2] [3] Radium-223, a fırst-inclass alpha-emitting radiopharmaceutical with a potent and highly targeted cytotoxic effect on bone metastases, has been approved for the treatment of patients with castrationresistant prostate cancer (CRPC) and symptomatic bone metastases with no known visceral metastatic disease in fırst-line and postdocetaxel settings. 4 Here, we review the mechanism of action of radium-223; its use in the treatment of prostate and breast cancer with skeletal metastases, including results from the ALSYMPCA phase III clinical trials and long-term follow-up; and an overview of current and planned studies using this agent.
RADIUM-223 MECHANISM OF ACTION
Radium-223 is an alpha-particle-emitting radioisotope that acts by delivering cytotoxic alpha-particle radiation to sites of bone metastases. 5, 6 As a calcium mimetic, radium-223 targets bone, forming complexes with the bone mineral hydroxyapatite. Moreover, it preferentially targets areas of high bone turnover, as present in bone metastases, with almost no redistribution of daughter nuclides (Fig. 1) . 5 Radium-223 has a half-life of 11.4 days and decays to radon-219, which subsequently (over fıve more stages) decays to lead-207. 6 Over the six-stage decay process, for each atom of radium-223 four alpha-particles (each composed of two protons and two neutrons) are released, representing 95% of the total radiation energy emitted. [5] [6] [7] The alpha-particles are believed to exert their cytotoxic action by inducing damaging double-strand breaks in the DNA of adjacent cells. 8, 9 After the generation of DNA breaks, cell death is initiated via numerous mechanisms or cellular pathways. 10 The cytocidal activity of radium-223 alpha-radiation appears to be largely independent of dose rate, oxygen levels, and cell cycle status. 5, 8, 10 In addition to DNA breaks, additional cytotoxicity mechanisms have been proposed for radium-223, including the potential involvement of reactive oxygen species. 10 
ADVANTAGES OF ALPHA-EMITTING PHARMACEUTICALS
particle range of the radionuclide selected. Initial clinical studies with bone-seeking compounds were conducted using only low-linear energy ␤-emitters (  89 strontium or   153 samarium), which have since been proven to be useful for pain palliation. 11-13 ␤-emitters have a relatively reduced radiobiologic effectiveness and are associated with substantial myelotoxicity (Table 1) . 11, 12, 14, 15 As a result, it has been diffıcult to show antitumor effects with these ␤-emitters because toxicity has limited the dosage given and the use of repeated treatments. 11, 12 To date, no large randomized placebo-controlled phase III studies have demonstrated a survival advantage for the ␤-emitters (Table 1) . Consequently, ␤-emitters are indicated for the treatment of pain associated with bone metastases whereas the alpha-emitter radium-223 is recommended for the treatment of CRPC with bone metastases.
Radionuclides that emit alpha-particles have high linear energy transfer radiation, resulting in an enhanced ability to induce DNA double-strand breaks compared with betaparticles. In contrast to beta-particles (e.g., strontium-89 or samarium-153), which can penetrate approximately 6 mm in biologic tissue, alpha-particles of radium-223 penetrate an ultrashort distance (less than 100 m; 2 to 10 cell diameters), thereby delivering a highly targeted effect while minimizing adverse effects, particularly those affecting bone marrow cell populations (Table 1) . [9] [10] [11] [12] [14] [15] [16] [17] Indeed, animal studies have shown the potential for radium-223 to deliver a therapeutically effective radiation dose to bone surfaces while minimizing the dose of radiation absorbed by bone marrow. 8 
EARLY PRECLINICAL DATA AND CLINICAL STUDIES WITH RADIUM-223
Preclinical experimental data and dosimetric estimates with targeted alpha-emitters suggested that these agents could deliver therapeutically relevant radiation to bone surfaces and skeletal metastases at dosages that should be tolerated by the bone marrow. 14 Radium-223 was selected as one of the few alpha-emitters with a half-life suitable to combat skeletal metastases. Preclinical studies using a nude rat model injected with human breast cancer cells and treated with radium-223 demonstrated a signifıcant antitumor effect for radium-223 at dosages well tolerated by the bone marrow (p Ͻ 0.05), 16 indicating that the agent would be a good candidate to combat bone metastases. As a result of these studies, we evaluated radium-223 in phase I and II clinical trials. 18, 19 As shown in Fig. 2 , eight clinical trials (phase I-III) with radium-223 have been completed since 2003. In an early fırst-in-human study composed of patients with breast and prostate cancer with skeletal metastases, we demonstrated that radium-223 was safe and well tolerated at all therapeutically relevant dosages (6, 93, 163, 213 , or 250 kBq/kg) (Fig.  2) . 8 In a subsequent randomized, phase II double-blind mul- 
KEY POINTS
⅐ Radium-223, a first-in-class, alpha-emitting radiopharmaceutical with a potent and highly targeted cytotoxic effect on bone metastases, has been approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases with no known visceral metastatic disease. ⅐ In the randomized phase III ALSYMPCA trial, radium-223 improved median overall survival versus placebo by 3.6 months, was well tolerated, had a low incidence of hematologic adverse events, and prolonged time to first symptomatic skeletal event by almost 6 months in patients with CRPC and symptomatic bone metastases; additional trials demonstrated that radium-223 had pain-relieving effects in up to 71% of patients. ⅐ To date, eight radium-223 clinical trials have been completed (phases I to III), with seven trials currently active and recruiting to assess dose-limiting toxicity, safety, and changes in alkaline phosphatase in patients with CRPC. ⅐ The first-in-human studies, composed of patients with breast and prostate cancer with skeletal metastases, demonstrated that radium-223 was safe and well tolerated at all therapeutically relevant dosages, whereas a phase IIa trial of patients with advanced breast cancer and progressive bone-dominant disease demonstrated that radium-223 targeted areas of increased bone metabolism and showed biologic activity. ⅐ The potential efficacy and contribution of radium-223 to current standard therapy for breast, osteosarcoma, and potentially other cancer types is being explored.
ticenter study, 122 patients with CRPC and bone metastases were randomly assigned to receive three injections of radium-223 at 6-week intervals, at doses of 25 kBq/kg (41 patients), 50 kBq/kg (39 patients), or 80 kBq/kg (42 patients). In this study we compared the proportion of patients in each dose group who had a confırmed decrease in baseline prostate-specifıc antigen (PSA) levels and demonstrated that radium-223 was well tolerated and had a dose-dependent effect on serum markers of CRPC activity, suggesting that control of bone disease with radium-223 may affect cancerrelated outcomes. 18 In an additional phase II study, 100 patients with CRPC and painful bone metastases were randomly assigned to a single intravenous dose of 5, 25, 50, or 100 kBq/kg radium-223 and evaluated for pain index (visual analog scale) and analgesic use (Fig. 2 ). There was a signifı-cant improvement in the Brief Pain Inventory functional index for all dose groups (p ϭ 0.04, 0.01, 0.002, and 0.02) and a decrease in bone alkaline phosphatase in the highest dose group. All doses were safe and well tolerated ( C-telopeptide (ICTP [p ϭ 0.011]) (Fig. 2) . Importantly, the median overall survival increased to 65.3 weeks for the radium-223-treated group, compared with 46.4 weeks for placebo. 20 The positive results from the phase II trials and the improvement in overall survival with radium-223 led to the inception of a large phase III randomized, placebocontrolled study to further evaluate the effıcacy and safety of radium-223 in patients with CRPC and symptomatic bone metastases. 21
RADIUM-223 AND CRPC
The ALSYMPCA study was a large (921 patients), randomized, double-blind, placebo-controlled, multicenter, phase III clinical trial (Fig. 3) . 21 The primary endpoint was overall survival in the intention-to-treat population. Key secondary endpoints focused on symptomatic skeletal events and changes in levels of the disease biomarkers PSA and ALP. Patients were randomly assigned in a 2:1 ratio to receive six 4-weekly intravenous injections of radium-223 (50 kBq per kilogram of body weight) or placebo. In addition to the injections, all patients received the best standard of care, defıned as the routine care provided at each center, which included possible use of ketoconazole, glucocorticoids, antiandrogens, estrogens, or local external beam radiation therapy (EBRT); however, use of chemotherapy, hemibody radiation therapy, or other radionuclides was not permitted. Before randomization, patients were stratifıed according to baseline ALP level (Ͻ 220 vs. Ն 220 U/L), current or no use of a bisphosphonate, and previous or no use of docetaxel. Patients were eligible to participate if they had symptomatic, histologically confırmed CRPC with at least two bone metastases and no known visceral metastases.
In the ALSYMPCA study, we found that radium-223 signifıcantly improved overall survival of CRPC patients with symptomatic bone metastases compared with placebo (primary endpoint) ( Table 1 and Fig. 3) . Patients who received radium-223 had a median overall survival of 14.9 months, compared with 11.3 months for patients who received placebo (hazard ratio [HR] 0.70, 95% confıdence interval [CI]; 0.58 to 0.83, p Ͻ 0.001). Additionally, radium-223 treatment, compared with placebo, was associated with a signifıcant delay in both the median time to fırst symptomatic skeletal event (15.6 vs. 9.8 months; HR ϭ 0.66, 95% CI; 0.52 to 0.83, p Ͻ 0.001) 21 and the time to an increase in the PSA level (3.6 vs. 3.4 months; HR ϭ 0.64, 95% CI; 0.54 to 0.77, p Ͻ 0.001). 21 Furthermore, radium-223 was also associated with a signifı-cant delay in the time to an increase in total ALP level compared with placebo (7.4 vs. 3.8 months; HR ϭ 0.17, 95% CI; 0.13 to 0.22, p Ͻ 0.001). 21 The ALSYMPCA study data also suggest that radium-223 has a benefıcial effect on pain (post hoc analyses published as abstracts) 22, 23 and health-related quality of life (HR-QOL; Table 1 ), 21 with the time to EBRT for bone pain being signifıcantly longer for the radium-223 group than for the placebo group (HR ϭ 0.67, 95% CI; 0.53 to 0.85), and median time to initial opioid use signifıcantly longer in the radium-223 group than with placebo (HR ϭ 0.621, 95% CI; 0.456 to 0.846). 22, 23 Finally, based on Functional Assessment of Cancer Therapy-Prostate (FACT-P) total scores, a signifıcantly higher percentage of patients in the radium-223 group, compared with the placebo group, had a clinically meaningful improvement in HR-QOL (score increased at least 10 points from baseline) over the period of drug administration (25% vs. 16%; p ϭ 0.02). 21 
RADIUM-223 AND BREAST CANCER
The fırst-in-human studies, which demonstrated that radium-223 was safe and well tolerated in patients with breast and prostate cancer and skeletal metastases, suggested that radium-223 may have effıcacy in patients with breast cancer with bone metastases (Fig. 2) . 5 In patients with breast cancer, bone metastases are common in advanced stages and are associated with increased morbidity and poor prognosis. In preclinical studies using in vitro models mimicking the prevention or treatment of breast skeletal metastasis, radium-223 was incorporated into bone matrix and inhibited the proliferation of breast cancer cells and the differentiation of osteoblasts and osteoclasts. In an established bone metastasis setting, radium-223 decreased osteolysis by 56% and tumor growth by 43%, and induced DNA double-strand breaks in breast cancer cells in vivo. 24 Finally, radium-223, either as a monotherapy or in combination with zoledronic acid or doxorubicin, extended survival in these in vivo studies compared with the vehicle group. These positive preclinical studies were the stimulus for clinical trials evaluating radium-223 in patients with metastatic breast cancer (MBC).
Up to 80% of patients with MBC develop bone metastases, and associated skeletal complications result in substantial morbidity. In a phase IIa study, radium-223 in addition to bisphosphonate therapy was given to patients with MBC who had bone-dominant cancer, had progressed on endocrine therapy, and were not candidates for further endocrine therapy. 25 Patients were scheduled to receive four intravenous injections of radium-223 (50 kBq per kilogram of body weight; one injection was given every 4 weeks. Overall, 15 of 23 patients received all four radium-223 injections, 19 of 23 patients had three, and all 23 patients had at least two injections). Osteoblastic lesions detected on bone scan with standardized uptake values (SUVs) greater than twice the normal liver uptake and with diameter greater than 15 mm on positron emission tomography computed tomography (PET CT) were defıned as target lesions and subsequently monitored. Sequential [
18 F]-fluorodeoxyglucose positron emission tomography ([ 18 F]-FDG PET) was performed at baseline, before the third study drug administration, and at treatment discontinuation to assess metabolic changes in target lesions (changes in SUV). One-third of target lesions showed signifıcant metabolic decrease (defıned as Ն25% reduction of maximum SUV from baseline or complete disappearance of lesions) after two radium-223 injections that persisted after all four injections. Most analyzed bone lesions showed stable disease, although many decreased in intensity (Fig. 2) . 25 These fındings demonstrated that radium-223 targets areas of increased bone metabolism caused by breast cancer bone metastases that could be assessed using sequential [ 
CURRENT AND FUTURE STUDIES WITH RADIUM-223
Currently, seven radium-223 clinical trials are active and recruiting ( Table 2 ). The ALSYMPCA trial is ongoing, with estimated completion in early 2014. Patients enter a designated follow-up period, 26 which starts 4 weeks after each patient's last injection and continues until 3 years after their fırst injection. Adverse events (AEs) considered to be treatment related by the investigator are reported during this follow-up. Long-term safety data are assessed by development of specifıc diseases, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, primary bone cancer, or primary cancer in other organs. Of the 921 patients enrolled in ALSYMPCA, 574 have entered the designated follow-up period (406 treated with radium-223, 168 treated with placebo) 21 (Table 3) . During the designated follow-up period, 322 (79%) radium-223-treated patients and 145 (86%) placebo patients withdrew from the study because of AEs, patient request, investigator request, death, disease progression, loss to follow-up, or other reasons. Thirtyseven treatment-related AEs were reported in 25 of 404 (6%) radium-223-treated patients and 8 of 167 (5%) placebo patients; primary cancer in other organs was reported in 5 patients (2 radium-223; 3 placebo). The incidence of myelosuppression among radium-223-treated patients was 3% or less. There were no reports of AML, MDS, or primary bone cancer. After a median of 1.5 years of follow-up, no additional safety signals have been identifıed so far. The longterm follow-up study for ALSYMPCA is still ongoing.
Several other radium-223 clinical trials are currently in the recruiting phase (Table 2) . A phase I/II study evaluating the safety and effıcacy of radium-223 with docetaxel in patients with CRPC and symptomatic bone metastases was recently initiated (NCT01106352). The phase I portion of this study has been completed and reported, 27 whereas the phase II segment is currently ongoing. The short half-life of radium-223 and the low rates of myelosuppression during treatment indicate that multiple dosing at relatively short intervals (4 weeks) is possible. The ability to administer multiple doses may potentially improve the radiation dose homogeneity, 8 a factor that might contribute to the overall survival benefıt demonstrated with radium-223 but not seen with beta-particle-emitting radionuclides. 28 Radium-223 was recently approved for up to six injections 6, 7 ; a trial evaluating the safety of re-treatment with six further radium-223 doses is currently under way (NCT01934790). 29 The low rates of myelosuppression observed with radium-223 have also raised interest in the potential use of radium-223 in combination with other agents. Trials investigating the use of radium-223 in combination with abiraterone (NCT02034552) 29 or docetaxel (NCT01106352) 29 are planned or are recruiting.
However, depending on the type of chemotherapy, additive myelosuppression remains possible. A single-arm prospective, interventional, open-label, multicenter early-access program in patients diagnosed with castrate-resistant, hormone-refractory prostate cancer with symptomatic bone metastases has been initiated to assess the acute and long-term safety of radium-223; the trial has closed recruitment in the United States (NCT01516762) but is still recruiting outside the United States (NCT01618370). 29 Finally, future studies evaluating the potential effıcacy and contribution of radium-223 dichloride to current standard therapy for breast, osteosarcoma, and other cancer types are being explored.
DISCUSSION AND CONCLUSION
The development of radium-223 has been very straightforward. There were clear indications from our fırst-in-human studies that radium-223 had an acceptable safety profıle, and the encouraging data regarding pain relief and overall survival have subsequently been verifıed in several randomized trials. In particular, radium-223 prolonged the time to symptomatic skeletal events (a more clinically relevant endpoint than asymptomatic radiologically detected events used in previous trials) by almost 6 months regardless of baseline variables, including the use of bisphosphonates at study entry, in addition to having a positive effect on patients' quality of life. Furthermore, given its mechanism of action targeting bone metastases, radium-223 has demonstrated a primary effect on serum ALP, signifıcantly delaying time to an increase in total ALP levels (p Ͻ 0.001).
In addition to radium-223, several other relatively new drugs, including abiraterone, cabazitaxel, and enzalutamide, have been approved for patients with metastatic CRPC. 4, 12, 30, 31 Abiraterone plus prednisone is considered as a fırst-line treatment option for patients with mild symptomatic metastases or those who have received prior docetaxel treatment because of the benefıt in overall survival, progressionfree survival, and QoL. Median overall survival for abiraterone/prednisone has been reported as 35.3 months, compared with 27.2 months for placebo (p ϭ 0.01). Grade 3 and 4 toxicities were reported in 48% of the patients on abiraterone/prednisone compared with 42% of placebo patients. 4, 30 Similar to abiraterone, enzalutamide is recommended because of its benefıt in overall survival, progression-free survival, and QoL, but as an effective second-line treatment option. Enzalutamide improved overall survival to 18.4 months, compared with 13.6 months in the placebo group (p Ͻ 0.001). Interestingly, 45% of patients treated with enzalutamide had grade 3/4 toxicities compared with 53% for the placebo group. Cabazitaxel is also used as a second-line option for patients administered prior docetaxel. In a recent phase III study, cabazitaxel resulted in a median overall survival of 15.1 months, compared with 12.7 months for patients receiving mitoxantrone (p Ͻ 0.0001). The cabazitaxel treatment group experienced more grade 3/4 hemato- logic toxicities than the placebo group, specifıcally neutropenia (82% vs. 58%), leukopenia (68% vs. 42%), and anemia (11% vs. 5%). 4, 30 In the combination setting, there are no data showing the order in which these new metastatic CRPC drugs should be administered, and it is anticipated that future clinical studies will demonstrate the optimal sequence of these new therapeutics. In contrast to the new endocrine modalities, radium-223 is a cytotoxic agent regardless of the proliferative status, hormone receptor status, or signaling events of the cell. Because of its unique mode of action and safety profıle, radium-223 has the potential to be combined with the new endocrine and immunologic therapeutic modalities for treatment of prostate and breast cancers with bone metastases.
In conclusion, radium-223 is a fırst-in-class alpha-particle-emitting radiopharmaceutical that is approved for the treatment of CRPC patients with symptomatic bone metastases and no known visceral metastases. It is an option in fırst-line and postdocetaxel settings for patients with CRPC and symptomatic bone metastases. The overall survival benefıt demonstrated by radium-223, combined with its tolerability profıle, makes this agent an effective novel treatment option for metastatic bone disease. Further studies are required to determine the optimal sequencing (and possible combination) of monotherapies in the treatment of this complex disease.
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